NDC 25682-028

Ultomiris

Ravulizumab

Ultomiris is a Intravenous Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Alexion Pharmaceuticals Inc.. The primary component is Ravulizumab.

Product ID25682-028_0584968e-282e-4a10-aa66-f0329d41f571
NDC25682-028
Product TypeHuman Prescription Drug
Proprietary NameUltomiris
Generic NameRavulizumab
Dosage FormSolution, Concentrate
Route of AdministrationINTRAVENOUS
Marketing Start Date2018-12-21
Marketing CategoryBLA / BLA
Application NumberBLA761108
Labeler NameAlexion Pharmaceuticals Inc.
Substance NameRAVULIZUMAB
Active Ingredient Strength1100 mg/11mL
Pharm ClassesComplement Inhibitor [EPC],Complement Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 25682-028-01

1 VIAL, GLASS in 1 CARTON (25682-028-01) > 11 mL in 1 VIAL, GLASS
Marketing Start Date2018-12-21
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Ultomiris" or generic name "Ravulizumab"

NDCBrand NameGeneric Name
25682-022Ultomirisravulizumab
25682-025Ultomirisravulizumab
25682-028Ultomirisravulizumab

Trademark Results [Ultomiris]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ULTOMIRIS
ULTOMIRIS
87713118 5716901 Live/Registered
Alexion Pharmaceuticals, Inc.
2017-12-08

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.